**Inclusion/Exclusion Criteria**

The following criteria for evidence inclusion for the MEDS Model Analysis was determined through the guidance of the BCBS Plans’ executive and clinical pharmacists**.**

**Inclusion Criteria**

|  |  |
| --- | --- |
| **Patient Population** | * Individuals ages 18 years and older with moderate-to-severe chronic plaque psoriasis * Randomized Controlled Trials: At least 50 patients |
| **Intervention** | * Secukinumab (Cosentyx) * Etanercept (Enbrel) * Adalimumab (Humira) * Infliximab (Remicade) * Brodalumab (Siliq) * Ustekinumab (Stelara) * Ixekizumab (Taltz) * Guselkumab (Tremfya) * Certolizumab (Cimzia) * Tildrakizumab (Ilumya) * Risankizumab (Skyrizi) * Apremilast (Otezla) |
| **Comparator** | * Head to Head * Placebo |
| **Outcomes** | Efficacy Outcomes:   * Psoriasis Area and Severity Index (PASI) 90 (30% weight) * Physician Global Assessment (PGA) or Investigator’s Global Assessment (IGA) (‘clear’/’almost clear’) (70% weight)   Safety Outcomes   * Discontinuation (70% weight) * Severe Adverse Events (30% weight) |
| **Timing** | 10 – 24 weeks |
| **Setting** | Outpatient |

**Exclusion Criteria**

* Studies involving patients under 18
* Single-arm studies
* Open label long term extension studies (unless the study reported the blinded phase before crossover)
* Randomized controlled trials with sample size of less than 50 patients